{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:44:57Z","timestamp":1793227497510,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,24]],"date-time":"2022-03-24T00:00:00Z","timestamp":1648080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,24]],"date-time":"2022-03-24T00:00:00Z","timestamp":1648080000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Nigratine (also known as 6E11), a flavanone derivative of a plant natural product, was characterized as highly specific non-ATP competitive inhibitor of RIPK1 kinase, one of the key components of necroptotic cell death signaling. We show here that nigratine inhibited both necroptosis (induced by Tumor Necrosis Factor-\u03b1) and ferroptosis (induced by the small molecules glutamate, erastin, RSL3 or cumene hydroperoxide) with EC<jats:sub>50<\/jats:sub> in the \u00b5M range. Taken together, our data showed that nigratine is a dual inhibitor of necroptosis and ferroptosis cell death pathways. These findings open potential new therapeutic avenues for treating complex necrosis-related diseases.<\/jats:p>","DOI":"10.1038\/s41598-022-09019-w","type":"journal-article","created":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T03:02:39Z","timestamp":1648177359000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Nigratine as dual inhibitor of necroptosis and ferroptosis regulated cell death"],"prefix":"10.1038","volume":"12","author":[{"given":"Claire","family":"Delehouz\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Comte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen Adonai","family":"Leon-Icaza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Cougoule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelle","family":"Hauteville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Goekjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeannette Chlo\u00eb","family":"Bulinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Th\u00e9r\u00e8se","family":"Dimanche-Boitrel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne","family":"Meunier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgane","family":"Rousselot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7186-7483","authenticated-orcid":false,"given":"St\u00e9phane","family":"Bach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,24]]},"reference":[{"key":"9019_CR1","doi-asserted-by":"publisher","first-page":"7640","DOI":"10.1021\/acs.jmedchem.8b00610","volume":"61","author":"A Gandini","year":"2018","unstructured":"Gandini, A. et al. Tau-centric multitarget approach for Alzheimer\u2019s disease: Development of first-in-class dual glycogen synthase kinase 3beta and tau-aggregation inhibitors. J. Med. Chem. 61, 7640\u20137656. https:\/\/doi.org\/10.1021\/acs.jmedchem.8b00610 (2018).","journal-title":"J. Med. Chem."},{"key":"9019_CR2","doi-asserted-by":"publisher","DOI":"10.1002\/med.21699","author":"C Albertini","year":"2020","unstructured":"Albertini, C., Salerno, A., SenaMurteira Pinheiro, P. & Bolognesi, M. L. From combinations to multitarget-directed ligands: A continuum in Alzheimer\u2019s disease polypharmacology. Med. Res. Rev. https:\/\/doi.org\/10.1002\/med.21699 (2020).","journal-title":"Med. Res. Rev."},{"key":"9019_CR3","doi-asserted-by":"crossref","unstructured":"Ehrlich, P. Beitr\u00e4ge zur Theorie und Praxis der histologischen F\u00e4rbung. The Collected Papers of Paul Ehrlich, London Pergamon, 29\u201064 (2013).","DOI":"10.1016\/B978-0-08-009054-2.50006-7"},{"key":"9019_CR4","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/nrd1346","volume":"3","author":"BL Roth","year":"2004","unstructured":"Roth, B. L., Sheffler, D. J. & Kroeze, W. K. Magic shotguns versus magic bullets: Selectively non-selective drugs for mood disorders and schizophrenia. Nat. Rev. Drug Discov. 3, 353\u2013359. https:\/\/doi.org\/10.1038\/nrd1346 (2004).","journal-title":"Nat. Rev. Drug Discov."},{"key":"9019_CR5","doi-asserted-by":"publisher","first-page":"485","DOI":"10.4155\/fmc.14.25","volume":"6","author":"M Rosini","year":"2014","unstructured":"Rosini, M. Polypharmacology: The rise of multitarget drugs over combination therapies. Future Med. Chem. 6, 485\u2013487. https:\/\/doi.org\/10.4155\/fmc.14.25 (2014).","journal-title":"Future Med. Chem."},{"key":"9019_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s40169-017-0181-2","author":"RR Ramsay","year":"2018","unstructured":"Ramsay, R. R., Popovic-Nikolic, M. R., Nikolic, K., Uliassi, E. & Bolognesi, M. L. A perspective on multi-target drug discovery and design for complex diseases. Clin. Transl. Med. https:\/\/doi.org\/10.1186\/s40169-017-0181-2 (2018).","journal-title":"Clin. Transl. Med."},{"key":"9019_CR7","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/s41418-017-0012-4","volume":"25","author":"L Galluzzi","year":"2018","unstructured":"Galluzzi, L. et al. Molecular mechanisms of cell death: Recommendations of the nomenclature committee on cell death 2018. Cell Death Differ. 25, 486\u2013541. https:\/\/doi.org\/10.1038\/s41418-017-0012-4 (2018).","journal-title":"Cell Death Differ."},{"key":"9019_CR8","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","volume":"149","author":"SJ Dixon","year":"2012","unstructured":"Dixon, S. J. et al. Ferroptosis: An iron-dependent form of nonapoptotic cell death. Cell 149, 1060\u20131072. https:\/\/doi.org\/10.1016\/j.cell.2012.03.042 (2012).","journal-title":"Cell"},{"key":"9019_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2021.631654","author":"A Aguilera","year":"2021","unstructured":"Aguilera, A. et al. Cell Death in cyanobacteria: Current understanding and recommendations for a consensus on its nomenclature. Front. Microbiol. https:\/\/doi.org\/10.3389\/fmicb.2021.631654 (2021).","journal-title":"Front. Microbiol."},{"key":"9019_CR10","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/nchembio711","volume":"1","author":"A Degterev","year":"2005","unstructured":"Degterev, A. et al. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat. Chem. Biol. 1, 112\u2013119. https:\/\/doi.org\/10.1038\/nchembio711 (2005).","journal-title":"Nat. Chem. Biol."},{"key":"9019_CR11","doi-asserted-by":"publisher","first-page":"9714","DOI":"10.1073\/pnas.1901179116","volume":"116","author":"A Degterev","year":"2019","unstructured":"Degterev, A., Ofengeim, D. & Yuan, J. Targeting RIPK1 for the treatment of human diseases. Proc. Natl. Acad. Sci. 116, 9714\u20139722. https:\/\/doi.org\/10.1073\/pnas.1901179116 (2019).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"9019_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16887-1","author":"AL Samson","year":"2020","unstructured":"Samson, A. L. et al. MLKL trafficking and accumulation at the plasma membrane control the kinetics and threshold for necroptosis. Nat. Commun. https:\/\/doi.org\/10.1038\/s41467-020-16887-1 (2020).","journal-title":"Nat. Commun."},{"key":"9019_CR13","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.tips.2020.01.002","volume":"41","author":"S Martens","year":"2020","unstructured":"Martens, S., Hofmans, S., Declercq, W., Augustyns, K. & Vandenabeele, P. Inhibitors targeting RIPK1\/RIPK3: old and new drugs. Trends Pharmacol. Sci. 41, 209\u2013224. https:\/\/doi.org\/10.1016\/j.tips.2020.01.002 (2020).","journal-title":"Trends Pharmacol. Sci."},{"key":"9019_CR14","doi-asserted-by":"publisher","first-page":"4402","DOI":"10.1038\/s41467-021-24712-6","volume":"12","author":"W Tonnus","year":"2021","unstructured":"Tonnus, W. et al. Dysfunction of the key ferroptosis-surveilling systems hypersensitizes mice to tubular necrosis during acute kidney injury. Nat. Commun. 12, 4402. https:\/\/doi.org\/10.1038\/s41467-021-24712-6 (2021).","journal-title":"Nat. Commun."},{"key":"9019_CR15","doi-asserted-by":"publisher","first-page":"3050","DOI":"10.1111\/febs.14176","volume":"284","author":"F Le Cann","year":"2017","unstructured":"Le Cann, F. et al. Sibiriline, a new small chemical inhibitor of receptor-interacting protein kinase 1, prevents immune-dependent hepatitis. FEBS J. 284, 3050\u20133068. https:\/\/doi.org\/10.1111\/febs.14176 (2017).","journal-title":"FEBS J."},{"key":"9019_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.112337","author":"M Benchekroun","year":"2020","unstructured":"Benchekroun, M. et al. Discovery of simplified benzazole fragments derived from the marine benzosceptrin B as necroptosis inhibitors involving the receptor interacting protein Kinase-1. Eur. J. Med. Chem. https:\/\/doi.org\/10.1016\/j.ejmech.2020.112337 (2020).","journal-title":"Eur. J. Med. Chem."},{"key":"9019_CR17","doi-asserted-by":"publisher","first-page":"12931","DOI":"10.1038\/s41598-017-12788-4","volume":"7","author":"C Delehouze","year":"2017","unstructured":"Delehouze, C. et al. 6E11, a highly selective inhibitor of receptor-interacting protein kinase 1, protects cells against cold hypoxia-reoxygenation injury. Sci. Rep. 7, 12931. https:\/\/doi.org\/10.1038\/s41598-017-12788-4 (2017).","journal-title":"Sci. Rep."},{"key":"9019_CR18","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1038\/nrd.2015.6","volume":"15","author":"M Conrad","year":"2016","unstructured":"Conrad, M., Angeli, J. P., Vandenabeele, P. & Stockwell, B. R. Regulated necrosis: Disease relevance and therapeutic opportunities. Nat. Rev. Drug Discov. 15, 348\u2013366. https:\/\/doi.org\/10.1038\/nrd.2015.6 (2016).","journal-title":"Nat. Rev. Drug Discov."},{"key":"9019_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2018.00214","author":"J Lewerenz","year":"2018","unstructured":"Lewerenz, J., Ates, G., Methner, A., Conrad, M. & Maher, P. Oxytosis\/ferroptosis\u2014(re-) emerging roles for oxidative stress-dependent non-apoptotic cell death in diseases of the central nervous system. Front. Neurosci. https:\/\/doi.org\/10.3389\/fnins.2018.00214 (2018).","journal-title":"Front. Neurosci."},{"key":"9019_CR20","doi-asserted-by":"publisher","first-page":"17013","DOI":"10.1038\/cddiscovery.2017.13","volume":"3","author":"K Ito","year":"2017","unstructured":"Ito, K. et al. MPP+ induces necrostatin-1- and ferrostatin-1-sensitive necrotic death of neuronal SH-SY5Y cells. Cell Death Discov. 3, 17013. https:\/\/doi.org\/10.1038\/cddiscovery.2017.13 (2017).","journal-title":"Cell Death Discov."},{"key":"9019_CR21","doi-asserted-by":"crossref","unstructured":"Chan, F. K.-M., Moriwaki, K. & De Rosa, M. J. in Immune Homeostasis Methods in Molecular Biology Ch. Chapter 7, 65\u201370 (2013).","DOI":"10.1007\/978-1-62703-290-2_7"},{"key":"9019_CR22","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1038\/cdd.2017.65","volume":"24","author":"S Grootjans","year":"2017","unstructured":"Grootjans, S., Vanden Berghe, T. & Vandenabeele, P. Initiation and execution mechanisms of necroptosis: An overview. Cell Death Differ. 24, 1184\u20131195. https:\/\/doi.org\/10.1038\/cdd.2017.65 (2017).","journal-title":"Cell Death Differ."},{"key":"9019_CR23","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.tcb.2015.10.014","volume":"26","author":"WS Yang","year":"2016","unstructured":"Yang, W. S. & Stockwell, B. R. Ferroptosis: Death by lipid peroxidation. Trends Cell Biol. 26, 165\u2013176. https:\/\/doi.org\/10.1016\/j.tcb.2015.10.014 (2016).","journal-title":"Trends Cell Biol."},{"key":"9019_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20194968","author":"D Kajarabille","year":"2019","unstructured":"Kajarabille, D. & Latunde, D. Programmed cell-death by ferroptosis: Antioxidants as mitigators. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms20194968 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"9019_CR25","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/s41419-019-2202-0","volume":"11","author":"ZX Hu","year":"2020","unstructured":"Hu, Z. X. et al. VDR activation attenuate cisplatin induced AKI by inhibiting ferroptosis. Cell Death Dis. 11, 2 (2020).","journal-title":"Cell Death Dis."},{"key":"9019_CR26","doi-asserted-by":"publisher","first-page":"5033","DOI":"10.1172\/Jci129903","volume":"129","author":"F Deng","year":"2019","unstructured":"Deng, F., Sharma, I., Dai, Y. B., Yang, M. & Kanwar, Y. S. Myo-inositol oxygenase expression profile modulates pathogenic ferroptosis in the renal proximal tubule. J. Clin. Investig. 129, 5033\u20135049. https:\/\/doi.org\/10.1172\/Jci129903 (2019).","journal-title":"J. Clin. Investig."},{"key":"9019_CR27","doi-asserted-by":"publisher","first-page":"2647","DOI":"10.1681\/Asn.2014080741","volume":"26","author":"YF Xu","year":"2015","unstructured":"Xu, Y. F. et al. A role for tubular necroptosis in cisplatin-induced AKI. J. Am. Soc. Nephrol. 26, 2647\u20132658. https:\/\/doi.org\/10.1681\/Asn.2014080741 (2015).","journal-title":"J. Am. Soc. Nephrol."},{"key":"9019_CR28","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1016\/s0140-6736(95)92057-9","volume":"346","author":"HR Brady","year":"1995","unstructured":"Brady, H. R. & Singer, G. G. Acute renal failure. Lancet 346, 1533\u20131540. https:\/\/doi.org\/10.1016\/s0140-6736(95)92057-9 (1995).","journal-title":"Lancet"},{"key":"9019_CR29","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1002\/biot.200600223","volume":"2","author":"D Guiffant","year":"2007","unstructured":"Guiffant, D. et al. Identification of intracellular targets of small molecular weight chemical compounds using affinity chromatography. Biotechnol. J. 2, 68\u201375 (2007).","journal-title":"Biotechnol. J."},{"key":"9019_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2019.112025","author":"D Sun","year":"2020","unstructured":"Sun, D. et al. Dual-target kinase drug design: Current strategies and future directions in cancer therapy. Eur. J. Med. Chem. https:\/\/doi.org\/10.1016\/j.ejmech.2019.112025 (2020).","journal-title":"Eur. J. Med. Chem."},{"key":"9019_CR31","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/S0040-4020(01)92024-1","volume":"37","author":"M Hauteville","year":"1981","unstructured":"Hauteville, M., Chopin, J., Geiger, H. & Schuler, L. Protogenkwanin, a new flavonoid from equisetum-arvense L. Tetrahedron 37, 377\u2013381. https:\/\/doi.org\/10.1016\/S0040-4020(01)92024-1 (1981).","journal-title":"Tetrahedron"},{"key":"9019_CR32","doi-asserted-by":"publisher","DOI":"10.1111\/mmi.14824","author":"N Iakobachvili","year":"2021","unstructured":"Iakobachvili, N. et al. Mycobacteria-host interactions in human bronchiolar airway organoids. Mol. Microbiol. https:\/\/doi.org\/10.1111\/mmi.14824 (2021).","journal-title":"Mol. Microbiol."},{"key":"9019_CR33","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2018100300","author":"N Sachs","year":"2019","unstructured":"Sachs, N. et al. Long-term expanding human airway organoids for disease modeling. EMBO J. https:\/\/doi.org\/10.15252\/embj.2018100300 (2019).","journal-title":"EMBO J."},{"key":"9019_CR34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0214250","author":"AH Kahn-Kirby","year":"2019","unstructured":"Kahn-Kirby, A. H. et al. Targeting ferroptosis: A novel therapeutic strategy for the treatment of mitochondrial disease-related epilepsy. PLoS ONE https:\/\/doi.org\/10.1371\/journal.pone.0214250 (2019).","journal-title":"PLoS ONE"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-09019-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-09019-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-09019-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T00:59:25Z","timestamp":1669337965000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-09019-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,24]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["9019"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-09019-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,24]]},"assertion":[{"value":"23 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Claire Delehouz\u00e9, Marie-Th\u00e9r\u00e8se Dimanche-Boitrel, Morgane Rousselot and St\u00e9phane Bach are the founders and members of the scientific advisory board of SeaBeLife Biotech, which is developing novel therapies for treating liver and kidney acute disorders. Peter Goekjian is member of the scientific advisory board of SeaBeLife Biotech. The other authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5118"}}